A clinical perspective of the U.S. anti-vaccination epidemic: Considering marginal costs and benefits, CDC best practices guidelines, free riders, and herd immunity

Michael G Anderson; Eric A Ballinger; David Benjamin; Lawrence D Frenkel; C William Hinnant Jr; Karin W Zucker

doi:10.1016/j.vaccine.2020.10.068

A clinical perspective of the U.S. anti-vaccination epidemic: Considering marginal costs and benefits, CDC best practices guidelines, free riders, and herd immunity

Vaccine. 2020 Nov 25;38(50):7877-7879. doi: 10.1016/j.vaccine.2020.10.068. Epub 2020 Oct 28.

Authors

Michael G Anderson¹, Eric A Ballinger², David Benjamin³, Lawrence D Frenkel⁴, C William Hinnant Jr⁵, Karin W Zucker⁶

Affiliations

¹ American College of Legal Medicine, Inc., Chicago, United States; University of Illinois College of Medicine, Chicago, Rockford, IL, United States; Magistrate Court of Cherokee County, GA, United States. Electronic address: mander10@uic.edu.
² Magistrate Court of Cherokee County, GA, United States.
³ Northeastern University School of Pharmacy, Boston, MA, United States.
⁴ University of Illinois College of Medicine, Chicago, Rockford, IL, United States.
⁵ American College of Legal Medicine, Inc., Chicago, United States; Clemson University, Department of Public Health Sciences, Clemson, SC, United States; Limestone College, Department of Health Sciences, Gaffney, SC, United States.
⁶ Baylor University, Hankamer School of Business, Army Med. Dept., Waco, TX, United States.

PMID: 33129607
DOI: 10.1016/j.vaccine.2020.10.068

No abstract available

Keywords: ACIP; Anti-vaccination; Bio-ethics; Counter-marketing; Empathy; Free-riders; Hesitant; Immunization guidelines; Public health; Risk-selection incentives; Vaccine performance ratio.

MeSH terms

Advisory Committees
Centers for Disease Control and Prevention, U.S.
Cost-Benefit Analysis
Epidemics*
Immunity, Herd*
Immunization Schedule
United States / epidemiology
Vaccination